Highest-materiality recent filing
Xenetic Biosciences Q1 2026 net loss down 49% to $0.5M; royalty revenue up 36% to $0.8M
Net loss of $0.5M ($0.04 per share) vs $0.9M a year ago; cash $7.3M at March 31, 2026.
Xenetic Biosciences grants 100,000 restricted shares to Interim CEO James Parslow
Grant of 100,000 restricted shares to James Parslow, Interim CEO and CFO.
Xenetic Biosciences reports 2025 net loss $2.7M, cash $7.9M, advances DNase program
Net loss $2.7M for FY2025; royalty revenue from Takeda sublicense rose 19% to $3.0M.
Xenetic Biosciences adjourns 2025 Annual Meeting again; no quorum achieved
Annual Meeting adjourned from Dec 11, 2025 to Jan 8, 2026 to seek quorum; reconvened but still lacked quorum.
Xenetic Biosciences adjourns 2025 Annual Meeting to Jan 8, 2026 due to lack of quorum
Annual Meeting convened Dec 11, 2025 adjourned without business due to insufficient quorum.
Xenetic Biosciences Q3 net loss ~$0.5M, revenue up 67% to $1.0M; cash extended by $3.9M offering
Net loss of approximately $0.5M for Q3 2025; revenue rose 67% YoY to $1.0M on higher Takeda royalty payments.
Xenetic Biosciences prices $4.5M underwritten offering of 735,000 shares at $6.12/share
Offering of 735,000 common shares at $6.12 each for gross proceeds of ~$4.5M; net proceeds ~$3.9M after discounts and expenses.
Xenetic Biosciences Q2 2025 net loss $0.7M; cash $4.8M; expands Scripps partnership
Net loss ~$0.7M for Q2 2025; no revenue reported.
Xenetic Biosciences Q1 2025: net loss $0.9M, revenue $0.6M (+16%), cash $5.2M
Net loss of ~$0.9M for Q1 2025; revenue increased 16.1% to ~$0.6M from $0.5M in Q1 2024.
Xenetic Biosciences' auditor Marcum resigns due to acquisition; CBIZ engaged as new auditor
Marcum resigned as auditor on April 8, 2025, after CBIZ acquired its attest business; Audit Committee approved.
Xenetic Biosciences reports FY2024 net loss of ~$4.0M, cash $6.2M, advances DNase program
Net loss for FY2024 ~$4.0M; R&D expenses $3.3M (down 5.9% YoY), G&A $3.4M (down 4.1%).
Xenetic Biosciences FY2024 net loss $4.0M; cash $6.2M; advancing DNase I to IND
Net loss ~$4.0M for FY2024; R&D expenses fell 5.9% to $3.3M from $3.5M YoY.
Xenetic Biosciences reports results of 2024 annual meeting; all proposals pass
All six director nominees elected; for votes ranged from 458,022 to 486,395; broker non-votes 391,780.
Net loss of $0.4M for Q3 2024; no material revenue reported.
Xenetic extends Scripps collaboration with $400k funding for DNase platform
Extended Research Funding & Option Agreement with Scripps Research by 12 months; total funding up to ~$400,000.
Two Xenetic directors not standing for re-election at 2024 Annual Meeting
James E. Callaway and Adam Logal will not stand for re-election at the 2024 Annual Meeting of Stockholders.
Xenetic Biosciences Q2 net loss $1.3M; cash $7.3M; DNase program advancing
Net loss of $1.3M for Q2 2024; R&D expenses flat at $0.9M; G&A up 19.5% to $1.1M on severance.
James Parslow appointed Interim CEO effective May 16, 2024; base salary increased to $400,000.
Xenetic Biosciences CEO Eisenberg and CSO Lockshin depart; CFO Parslow named interim CEO
Jeffrey F. Eisenberg stepped down as CEO and resigned as director effective May 16, 2024.
Xenetic Biosciences reports Q1 2024 net loss of $1.2M; cash at $7.8M
Net loss of approximately $1.2M for Q1 2024; R&D expenses up 58.6% to $0.9M on DNase preclinical work.
Xenetic Biosciences reports FY2023 net loss of $4.1M; cash at $9.0M
Net loss of $4.1M for year ended Dec 31, 2023; R&D expenses down 26.7% to $3.5M.
Xenetic Biosciences posts investor video by CSO on DNase I oncology preclinical data
Chief Scientific Officer Curis Lockshin, PhD, discusses preclinical data from DNase I oncology platform.
Xenetic Biosciences shareholders reject non-binding say-on-pay proposal at 2023 annual meeting
Nine director nominees elected; Dr. Dmitry Genkin received highest 'for' votes (461,413), Jeffrey Eisenberg lowest (255,632).
Xenetic Biosciences reports Q3 net loss of $1.1M; R&D spend up 156% on DNase platform
Net loss of $1.1M for Q3 2023; cash at $9.8M.
Xenetic Biosciences Q2 net loss $1.1M; expands DNase platform with VolitionRx SOW
Net loss of ~$1.1M for Q2 2023; R&D expenses fell 56.5% to ~$0.9M vs $2.1M in Q2 2022.
Xenetic Biosciences furnishes updated corporate presentation for investor meetings
Presentation dated June 2023; no specific financial or operational updates disclosed in the filing.
Xenetic Biosciences regains Nasdaq minimum bid price compliance
Received Nasdaq letter on May 30, 2023 confirming compliance with Listing Rule 5550(a)(2).
Xenetic Biosciences announces 1-for-10 reverse stock split effective May 15, 2023
Reverse split reduces outstanding shares from 15,166,596 to ~1,516,660; authorized shares from 100M to 10M.
Xenetic Biosciences Q1 net loss $0.9M; cash $12M; Takeda royalties up 55.7%
Net loss of $0.9M for Q1 2023; R&D expenses down 46% to $0.6M from $1.1M.
Xenetic Biosciences FY 2022 net loss $6.6M; cash $13.1M; DNase platform advances toward Phase 1
Net loss for FY 2022 was approximately $6.6 million; R&D expenses rose 50.8% to $4.8M.
Xenetic stockholders approve increase in authorized common stock from 50M to 100M shares
Proposal Four passed: 7,204,486 For, 1,131,034 Against, 110,245 Abstained, no broker non-votes.
Xenetic Biosciences annual meeting adjourned on share-increase proposal; all directors elected
Elected all 7 director nominees: Borisenko, Callaway, Dastoor, Eisenberg, Kornberg, Logal, Vinogradov.
Xenetic Biosciences receives Nasdaq extension to May 29, 2023 to regain $1 bid price compliance
Nasdaq granted an additional 180 calendar days, until May 29, 2023, to meet the $1.00 minimum bid price requirement.
Xenetic Biosciences reports Q3 2022 net loss of $0.8M; cash of $13.8M
Net loss for Q3 2022 was approximately $0.8 million.
Xenetic Biosciences issues 850,000 shares to CLS Therapeutics for patent rights
Issued 850,000 common shares to CLS Therapeutics LLC as consideration for assignment of certain patent rights.
Xenetic Biosciences reports Q2 net loss of $2.7M; advances DNase platform toward Phase 1 study
Net loss of approx $2.7M for Q2 2022; R&D expense rose 296% to $2.1M, including $1.3M IPR&D for DNase license.
Xenetic enters manufacturing agreement with Catalent for DNase clinical supply up to $5M
Estimated project cost up to ~$5M for cGMP manufacturing of Human DNase I over ~17 months.
Xenetic Biosciences receives Nasdaq minimum bid price deficiency notice
Nasdaq notified Xenetic on June 3, 2022 that its common stock bid price was below $1.00 for 30 consecutive business days.
Upfront payment: $500K cash + 875,000 common shares (250,000 issued to OPKO per third-party obligation).
Xenetic reports FY2021 net loss of $5.6M; royalty revenue up 166% to $1.2M
Net loss for FY2021 was approx $5.6M; R&D expenses rose to $3.2M (vs $1.7M in 2020) on XCART investment.
All seven director nominees elected; broker non-votes of 4,463,160 for each.
Xenetic Biosciences enters $4M ATM equity offering with H.C. Wainwright
Entered ATM Agreement with H.C. Wainwright as exclusive agent to sell up to $4M of common stock.
Warrants to purchase 129,084 shares exchanged for 51,634 common shares (0.4 ratio); all warrants cancelled.
Xenetic Biosciences reports Q3 net loss of ~$1.4M; cash $19.7M after $12.5M private placement
Net loss ~$1.4M for Q3 2021; R&D expenses up 36.1% to $0.8M, G&A up 17.5% to $0.9M.
Entered Amendment Number One to Master Service Agreement to terminate the prior Work Order with Pharmsynthez.
XCART targets tumor-specific antigens independent of CD19, advancing toward a Phase 1 study.
Xenetic Biosciences reports Q2 2021 net loss of $1.1M; completes $12.5M private placement
Net loss $1.1M for Q2 2021; cash $9.3M at quarter end.
Closed private placement of 4,629,630 shares at $2.70 per share for gross proceeds of $12.5M; H.C. Wainwright as placement agent.
Director Dmitry Genkin resigns from Xenetic Biosciences board
Dr. Dmitry Genkin resigned from the Board of Directors on July 15, 2021.
On October 29, 2024, James E. Callaway and Adam Logal, each a member of the board of directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”), informed the Company of their intention to not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders.
On October 29, 2024, James E. Callaway and Adam Logal, each a member of the board of directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”), informed the Company of their intention to not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders.
and Curtis Lockshin, the Company’s former Chief Scientific Officer
the Company entered into a confidential separation agreement and general release with each of and Jeffrey F. Eisenberg, the Company’s former Chief Executive Officer
the Board of Directors of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.
and in connection therewith, Mr. Eisenberg resigned as a director of the Company and all of its subsidiaries, as applicable.
In addition on May 16, 2024, the Company and Dr. Curtis Lockshin mutually agreed that Dr. Lockshin would step down as the Chief Scientific Officer of the Company, effective immediately.
On May 16, 2024, the Company and Jeffrey F. Eisenberg mutually agreed that Mr. Eisenberg would step down as the Chief Executive Officer of the Company, effective immediately
On May 16, 2024, the Board of Directors (the “Board”) of Xenetic Biosciences, Inc. (the “Company”) appointed James F. Parslow, the Company’s Chief Financial Officer, to the position of Interim Chief Executive Officer.
On July 15, 2021, Dr. Dmitry Genkin resigned as a member of the Board of Directors of Xenetic Biosciences, Inc.
Max materiality 0.75 · Median 0.50 · Most common event earnings